{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T01:42:59Z","timestamp":1770774179588,"version":"3.50.0"},"reference-count":21,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2010,11,17]],"date-time":"2010-11-17T00:00:00Z","timestamp":1289952000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Deutsche Derma Gesell"],"published-print":{"date-parts":[[2011,4]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Immune\u2010modifying monoclonal antibodies may induce or enhance the natural immune response against tumor cells. The complex interaction between antigen\u2010presenting cells and T lymphocytes as an immune response is strongly affected by anti\u2010CD152 (CTLA\u20104)\u2010antibodies. The cytotoxic T\u2010lymphocyte (CTLA\u20104) receptor binds molecules of the B7\u2010family which leads to a suppression of T cells. Specific CTLA\u20104 antibodies induce an unrestrained T\u2010cell activation. Treatment with the CTLA\u20104 antibodies ipilimumab and tremelimumab has been investigated in metastatic melanoma only within clinical trials. Currently, the critical phase III trial on ipilimumab is in the final analysis process and expected to lead to approval.<\/jats:p><jats:p>CTLA\u20104 antibodies belong to the most promising new molecules for the treatment of advanced melanoma. During treatment with CTLA\u20104 antibodies, distinct adverse events may occur. Treating physicians must be familiar with their appropriate treatment and prophylaxis. The most frequently observed side effects are diseases such as an autoimmune colitis which is typically characterized by a mild to moderate, but occasionally also severe and persistent diarrhea. Other autoimmune\u2010mediated side effects like hypophysitis, hepatitis, iridocyclitis or an exacerbation of lupus nephritis have been reported in the literature. Their early recognition and treatment are mandatory to reduce the risk of sequelae for CTLA\u20104\u2010antibod\u2010treated patients. Autoimmune\u2010mediated side effects are reported to correlate positively with treatment response. We review the mechanisms of action, provide an update on clinical trials with the two CTLA\u20104\u2010antibodies for metastatic melanoma, and present detailed recommendations for managing the side effects of these new agents.<\/jats:p>","DOI":"10.1111\/j.1610-0387.2010.07568.x","type":"journal-article","created":{"date-parts":[[2010,11,17]],"date-time":"2010-11-17T13:21:49Z","timestamp":1290000109000},"page":"277-286","source":"Crossref","is-referenced-by-count":36,"title":["Treatment and side effect management of CTLA\u20104 antibody therapy in metastatic melanoma"],"prefix":"10.1111","volume":"9","author":[{"given":"Katharina C.","family":"K\u00e4hler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Hauschild","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,11,17]]},"reference":[{"key":"e_1_2_11_2_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.23.021704.115611"},{"key":"e_1_2_11_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.5716"},{"key":"e_1_2_11_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2006.01.011"},{"key":"e_1_2_11_5_2","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.lba9011","article-title":"Phase III, open\u2010label, randomized, comparative study of tremelimumab (CP\u2010675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma","volume":"26","author":"Ribas A","year":"2008","journal-title":"J Clin Oncol"},{"key":"e_1_2_11_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70334-1"},{"key":"e_1_2_11_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq013"},{"key":"e_1_2_11_8_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1024"},{"key":"e_1_2_11_9_2","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1200\/jco.2009.27.15_suppl.9041","article-title":"Effect of ipilimumab at 10 mg\/kg on disease control in patients (pts) with M1c\u2010stage melanoma in relation to baseline lactate dehydrogenase (LDH) levels","volume":"27","author":"Smylie M","year":"2009","journal-title":"J Clin Oncol"},{"key":"e_1_2_11_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466"},{"key":"e_1_2_11_11_2","volume-title":"Poster presented at: Annual Meeting of the American Society of Clinical Oncology","author":"Lawrence D P","year":"2010"},{"key":"e_1_2_11_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1610-0387.2009.07028_supp.x"},{"key":"e_1_2_11_13_2","unstructured":"LebbeC O\u2019DayS Chiarion SileniV GajewskiT PehambergerH BondarenkoI QueiroloP LundgrenS RomanL VerschraegenC IbrahimR ChinK HoosA MaioM.Analysis of the onset and resolution of immune\u2010related adverse events during treatment with ipilimumab in patients with meta\u2010stastic melanoma. (oral abstract O\u2010015 Perspectives in Melanoma XII 2008)."},{"key":"e_1_2_11_14_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0830997100"},{"key":"e_1_2_11_15_2","article-title":"An analysis of the effectiveness of specific guidelines for the management of ipilimumab\u2010mediated diarrhea\/colitis: Prevention of gastrointestinal perforation and\/or colectomy","volume":"26","author":"Lin R","year":"2008","journal-title":"J Clin Oncol"},{"key":"e_1_2_11_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-008-0641-z"},{"key":"e_1_2_11_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0b013e32832e0bff"},{"key":"e_1_2_11_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-200411000-00008"},{"key":"e_1_2_11_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.06.205"},{"key":"e_1_2_11_20_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0187"},{"key":"e_1_2_11_21_2","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1200\/jco.2009.27.15_suppl.9034","article-title":"Association between immune\u2010related adverse events (irAEs) and disease control or overall survival in patients (pts) with advanced melanoma treated with 10 mg\/kg ipilimumab in three phase II clinical trials","volume":"27","author":"Lutzky J","year":"2009","journal-title":"J Clin Oncol"},{"key":"e_1_2_11_22_2","first-page":"28","article-title":"Association of adverse events and tumor response in melanoma patients treated with tremelimumab","author":"Pavlov D","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["JDDG: Journal der Deutschen Dermatologischen Gesellschaft"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1610-0387.2010.07568.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1610-0387.2010.07568.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T03:35:03Z","timestamp":1697427303000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1610-0387.2010.07568.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11,17]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["10.1111\/j.1610-0387.2010.07568.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1610-0387.2010.07568.x","archive":["Portico"],"relation":{},"ISSN":["1610-0379","1610-0387"],"issn-type":[{"value":"1610-0379","type":"print"},{"value":"1610-0387","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11,17]]}}}